Given the documented effectiveness of GLUT-1 inhibitors in various cancer cells (lymphoma, prostate cancer, gastric cancer) [24] we examined the effect of our GLUT-1 inhibitors on mesothelioma cells. The gene discussed is SLC2A1; the disease is prostate cancer.